Trends in Use, Cost, and Outcomes of Human Recombinant Erythropoietin, 1989-98

In this article the authors present descriptive data showing trends in human recombinant erythropoietin (EPO) doses, charges, and patient hematocrits from the fourth quarter of calendar year 1989 to the first quarter of 1998 for all recipients and recent data for patients treated by in-center hemodi...

Descripción completa

Detalles Bibliográficos
Autores principales: Greer, Joel W., Milam, Roger A., Eggers, Paul W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: CENTERS for MEDICARE & MEDICAID SERVICES 1999
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194623/
https://www.ncbi.nlm.nih.gov/pubmed/10558020
_version_ 1782339148364906496
author Greer, Joel W.
Milam, Roger A.
Eggers, Paul W.
author_facet Greer, Joel W.
Milam, Roger A.
Eggers, Paul W.
author_sort Greer, Joel W.
collection PubMed
description In this article the authors present descriptive data showing trends in human recombinant erythropoietin (EPO) doses, charges, and patient hematocrits from the fourth quarter of calendar year 1989 to the first quarter of 1998 for all recipients and recent data for patients treated by in-center hemodialysis. In 1997 nearly all in-center hemodialysis patients received EPO regularly at an average cost per recipient of $6,245 per year for total allowed charges of $842.2 million per year. The study shows that policy changes may have both anticipated and unanticipated effects on medical practice.
format Online
Article
Text
id pubmed-4194623
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher CENTERS for MEDICARE & MEDICAID SERVICES
record_format MEDLINE/PubMed
spelling pubmed-41946232014-11-04 Trends in Use, Cost, and Outcomes of Human Recombinant Erythropoietin, 1989-98 Greer, Joel W. Milam, Roger A. Eggers, Paul W. Health Care Financ Rev Research Article In this article the authors present descriptive data showing trends in human recombinant erythropoietin (EPO) doses, charges, and patient hematocrits from the fourth quarter of calendar year 1989 to the first quarter of 1998 for all recipients and recent data for patients treated by in-center hemodialysis. In 1997 nearly all in-center hemodialysis patients received EPO regularly at an average cost per recipient of $6,245 per year for total allowed charges of $842.2 million per year. The study shows that policy changes may have both anticipated and unanticipated effects on medical practice. CENTERS for MEDICARE & MEDICAID SERVICES 1999 /pmc/articles/PMC4194623/ /pubmed/10558020 Text en
spellingShingle Research Article
Greer, Joel W.
Milam, Roger A.
Eggers, Paul W.
Trends in Use, Cost, and Outcomes of Human Recombinant Erythropoietin, 1989-98
title Trends in Use, Cost, and Outcomes of Human Recombinant Erythropoietin, 1989-98
title_full Trends in Use, Cost, and Outcomes of Human Recombinant Erythropoietin, 1989-98
title_fullStr Trends in Use, Cost, and Outcomes of Human Recombinant Erythropoietin, 1989-98
title_full_unstemmed Trends in Use, Cost, and Outcomes of Human Recombinant Erythropoietin, 1989-98
title_short Trends in Use, Cost, and Outcomes of Human Recombinant Erythropoietin, 1989-98
title_sort trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194623/
https://www.ncbi.nlm.nih.gov/pubmed/10558020
work_keys_str_mv AT greerjoelw trendsinusecostandoutcomesofhumanrecombinanterythropoietin198998
AT milamrogera trendsinusecostandoutcomesofhumanrecombinanterythropoietin198998
AT eggerspaulw trendsinusecostandoutcomesofhumanrecombinanterythropoietin198998

Ejemplares similares